Purpose: To determine frequency, causes, and phenomenology of late seizure recurrence (SR) in patients with juvenile myoclonic epilepsy (JME) after remission of at least 1 year. Methods: Among 2722 epileptic patients from tertiary referral center, we retrospectively identified 105 patients (62 females; mean age 22.3 AE 7.2 years) with an established diagnosis of JME. All patients were treated with valproates (83.3%), or lamotrigine, topiramate, phenobarbital, add-on clobazam, or combinations (16.2%). Results: The median period of follow-up was 4.2 AE 3.2 (range: 1-17) years. SR occurred in 74 patients (70.5%) after median period of 2.4 AE 3.2 years. Twentytwo patients (29.7%) experienced myoclonic seizures (MS), 13 (17.7%) generalized tonic-clonic seizures (GTCS), 37 (50%) a combination of MS and GTCS, and two (2.6%) a combination of MS, GTCS and absence seizures. SR was associated most frequently with sleep deprivation and AED withdrawal, and rarely with alcohol intake, drug abuse, photostimulation, or menstruation. No provoking factors for SR were identified in 31.1% and 45% of cases with MS and GTCS, respectively. The majority of patients (59/74) had a single SR. A second SR occurred less frequently in patients in whom valproate dosage was increased after the first SR ( p = 0.0048). Conclusion: Late SR (mainly MS and GTCS) is detected frequently after prolonged follow-up in patients with JME despite the use of best-known therapy, usually due to AED withdrawal or erratic life style. Instead of futile efforts to persuade the patient to conform to restrictive life style, it is probably more efficient to use initial higher doses of AEDs.
Introduction
Juvenile myoclonic epilepsy (JME) is an age-related, idiopathic, generalized epileptic syndrome presenting with bilateral, arrhythmic myoclonic seizures (MS), generalized tonic-clonic seizures (GTCS), and less frequently typical absence seizures (AS). 1, 2 The most common factors that provoke seizures are sleep deprivation, fatigue, excessive alcohol intake, stress, photostimulation, and menstruation. 1, [3] [4] [5] Valproate (VPA) is the drug of choice that leads to complete remission of seizures in a majority of patients. 2, 6, 7 However, the frequency of seizure recurrence (SR) during long-term follow-up, despite VPA therapy, is not well known.
The aim of this study is to estimate frequency, causes, and phenomenology of late SR in patients with JME after at least a 1-year period of remission.
Patients and methods
Among 2722 epileptic patients from the Department of Epileptology of the Institute of Neurology CCS (tertiary referral center) hospitalized between January 1987 and December 2003, we retrospectively identified 137 patients with established diagnoses of JME. We used the clinical charts archive and electronic database containing all data regarding the first and all follow-up visits.
The diagnosis of JME was made if patients fulfilled all criteria according to Panayiotopoulos: 4 (1) presence of single or repetitive, arrhythmic, irregular MS, mainly occurring after awakening, predominantly in the arms; (2) normal neurological examination; (3) abnormal EEG findings presenting with generalized SW discharges (focal or background abnormalities were acceptable if other clinical criteria were justified); (4) normal CT/MR scans. Exclusion criteria were: (1) clinical and/or EEG evidence of myoclonic jerks secondary to brain hypoxia, metabolic diseases or other structural brain abnormalities; 8 (b) eyelid myoclonia with absence seizures; (c) self-induced epilepsy; (d) pure forms of photosensitive epilepsy; (e) poor drug compliance and (f) without remission during the first year.
Twenty patients satisfied exclusion criteria (two with eyelid myoclonia with absences, four with structural brain abnormalities; nine with poor drug compliance; five did not gain remission in the first year). Ten patients were lost for follow-up, and two patients dropped out due to their refusal to comply with AED regimen. Finally, 105 patients entered our cohort.
All patients were treated with antiepileptic drugs (AED) and followed on 6 month scheduled visits for at least 1 year. Additional visits were undertaken during 1 week following SR. Compliance was verified as reported by patients and by monitoring of plasma drug levels at each visit. Authors performed all follow-up visits, governed the therapy, determined SR, and estimated provoking factors (PF).
We defined SR as appearance of any type of solitary or repeated seizures that characterized JME (MS, GTCS, AS). Single SR completed during 24 h and multiple SR recurred in more than one 24 h period. AED withdrawal was diagnosed if the patient could confidently recall cessation in AED intake for more than 3 days (five times plasma half-life of VPA). Low plasma levels of AED (less than 50% of the level obtained at the 1-year visit) without clear anamnestic data of therapy cessation were also considered as AED withdrawal. The definition of other PF (sleep deprivation, photostimulation, menstruation, alcohol abuse, drug abuse, and emotional stress) is obvious by its name.
After a follow-up period of at least 1 year, all patients were divided into three groups according to the association of SR with PF. Patients without any SR during the follow-up period formed the first group (No_SR). Patients who had SR associated with obvious PF (usually with only one GTC in 6 months and less than five MS or AS per month) formed second group (PF_SR). Patients who had SR associated with no obvious PF (usually with two or more GTC in 6 months and more than five MS, or AS per month) formed the third group (NoPF_SR). Our policy was not to change the AED or its dose in the first two groups. However, in the third group, our policy was either to increase the dose of the original AED, to add another AED or to change therapy to different AED. After the dose had been changed, patients were followed for at least one additional year.
All patients signed forms of informed consent, approved by the Ethical Committee. Chi square, Mann-Whitney's, Kruskal-Wallis's test, Spearmen's coefficient of correlation, and descriptive statistics were used when indicated.
Results
After the introduction of AEDs, average period of follow-up was 4.2 AE 3.2 (range: 1-17) years. Demographic characteristics of the population, the number of patients with SR, and its timing are shown in Tables 1 and 2 .
During the first year, VPA was used as the first monotherapy in 91 (83.8%) patients (dose range 250-2500 mg). Half of the patients treated with VPA needed 500 mg or less and 3/4 needed 1000 mg or less for complete abolition of all seizures. Lamotrigine (up to 400 mg), topiramate (up to 400 mg), phenobarbital (up to 100 mg), clobazam (up to 30 mg), or combinations were used in 16.2% of patients for variety of pragmatic reasons.
SR was associated most frequently with sleep deprivation (in 46% with MS and 31.1% with GTCS) and AED withdrawal (in 15.9% with MS and 15.6% with GTCS). In 14 patients (18.9%) with AED withdrawal (all of them already treated with VPA), SR occurred in the form of GTCS (with or without MS) in eight patients, and in the form of sole MS in six patients. In all 14 patients, VPA was immediately reintroduced, and no second SR occurred during the remainder of follow-up.
Less frequently, alcohol intake, drug abuse, photostimulation, or menstruation also provoked seizures. Before therapy, EEG characteristics of photosensitivity were found in 17 patients (16.2%). However, photosensitivity was associated with either MS or GTCS in only seven (6.7%) patients.
After the start of the AED, no SR could be attributed to photosensitivity.
No PF were identified in 31.1% of patients with MS and 45% of patients with GTCS (group NoPF_SR). In two out of four patients with AS, PF for SR went unrecognized, while sleep deprivation in one, and emotional and physical stress in another patient were probable PF for SR.
In 36 out of 74 patients with SR (48.7%) obviously associated with PF (PF_SR group), the daily dose of AED remained unchanged. In this group, second SR occurred in 14 out of 36 (38.9%) patients during the rest of the observation period. In 38 out of 74 (51.3%) patients with SR not obviously associated with PF (NoPF_SR group), the daily dose of AED (VPA in all of them) was increased (250-750 mg of VPA were added) or supplementary therapy was introduced (lamotrigine was added to VPA in three patients). A second SR occurred in only four (10.5%) of these patients during the remainder of follow-up. The difference between the PF_SR group with the unchanged and the NoPF_SR group with increased dose of VPA was statistically significant ( p = 0.0048), favoring the group with increased dose.
Discussion
The SR occurred in 70% of our patients after a remission longer than 1 year, despite the bestknown therapy. Most frequently, SR occurred between 2 and 3 years after AED initiation, probably at the time when it appeared to patients that the epilepsy was gone. It is reasonable to assume that compliance to an AED regime was less strict, at least in some patients. 9 In the settings of regular and adequate AED therapy, the high rate of SR observed in our study has been rarely described previously, although the period of follow-up was shorter. 6 The long period of follow-up in our study is the key point that enabled the detection of late SR of GTCS even after more than 5 years (17 years in a single case) of regular AED therapy.
Approximately 1/10 of our patients had isolated MS prior to AED therapy, and all were treated with less than 750 mg of VPA. If any SR occurred, it was exclusively in the form of MS, possibly implying more benign course of JME in their cases. 1, 3, 4, 10 Detected PF for all seizure types at the onset of JME and at the time of SR (our group PF_SR) were very similar. Sleep deprivation was the most frequent factor that provoked SR, especially GTCS. AED withdrawal is the second most common but obviously the most important factor that provoked SR.
Although the prevalence of photosensitivity as PF of seizures in JME is 25-42%, it occurred in less than 16% of our patients despite meticulous use of recommended photostimulation techniques. 11 A low frequency (12%) of photosensitivity in our previous report may lead to speculation that older age of patients or ethnic difference may be a possible explanation. 12 Before therapy, seizures were associated with photosensitivity in only 6.7% of patients; upon use of VPA, it disappeared, although some experienced SR provoked by other PF. This could suggest that VPA therapy abolishes photosensitivity more effectively than seizures.
It has been stated that the identification and correction of common PF that provoke SR helps to better control seizures in JME. 4 However, it appears that the ''erratic'' life style (especially of adolescents) that could provoke seizure occurrence is difficult to correct. Our results suggest that if the AED dosage is increased in patients with SR and no obvious PF (NoPF_SR group), the probability of a second SR is significantly diminished. This contrasts with the finding that small doses of VPA (usually less than 1000 mg) have prolonged and complete effect against all seizures of JME. 1, 3, 6 However, it is reasonable to start with lower doses of VPA that may have long-term efficacy in approximately 30% of patients (our No_SR group). In a small number of patients with SR due to AED withdrawal (up to 18% in our group), alcohol, or drug abuse (PF_SR group), it is probably not justified to increase VPA dose but to improve the AED compliance. However, in the majority of patients, SR occurs spontaneously, or associated with milder PF for SR (''erratic'' life style). Because the risk of SR in this group (NoPF_SR) is higher, increasing the dose of AED is probably the most convenient solution. However, chronic adverse effects of AEDs may emerge 13 and the period between seizures may be quite long, which renders the benefit from chronic exposure of patients to higher doses of AEDs controversial.
In conclusion, it seems that the late SR equally in the form of MS and GTCS occurs frequently in patients with JME despite the best-known therapy. A period of follow-up longer than 1 year (probably of at least 3 years) is necessary to estimate seizure control in patients with JME. PF for SR often remain unrecognized, necessitating the application of a higher dosage of AEDs, which opens questions regarding the benign nature of this epileptic syndrome.
